. Author manuscript; available in PMC: 2020 Dec 1.

Published in final edited form as: J Pediatr. 2019 Sep 24;215:107–117.e12. doi: 10.1016/j.jpeds.2019.07.064

Table 1; online:

Comparison of demographic and clinical laboratory characteristics of atorvastatin-treated KD subjects and controls evaluated for protein carbonyl levels

	Atorvastatin KD subjects (N=9)	KD controls^† (N=18)	P value
Statin concentration 0.125 mg/kg, N	1	NA	NA
0.25 mg/kg, N	1	NA	NA
0.75 mg/kg, N	7	NA	NA
Age, y^*	2.9 (2.8-5.1)	3.5 (2.5-5.4)	0.8
Males, N (%)	8 (89)	13 (72)	0.6
Days of illness at sample collection^*
Pre-IVIG	5 (4-6)	5 (4-6)	0.7
2 weeks	20 (20-22)	20 (17-23)	0.6
White blood cell count, ×10⁹/L^*	11.7 (10.7-13.2)	10.4 (7.8-14.5)	0.4
CRP, mg/dL^*	8.1 (6.0-10.1)	5.5 (4.1-17.7)	1.0
ESR, mm/hr^*	60 (33-80)	42 (27-60)	0.6
ALT, IU/L^*	63 (35-107)	87 (46-108)	0.4
Zmax^*	3.2 (2.8-3.7)	2.0 (1.3-2.8)	0.1

Median (IQR)

^†

Controls are KD subjects treated only with IVIG and infliximab

WBC: white blood cell count, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, ALT: alanine aminotransferase, NA: Not applicable